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Abstract: Community-acquired pneumonia (CAP) remains a common cause of morbidity and 
a potentially life-threatening illness throughout the world mainly in elderly patients. Initial anti-
bacterial treatment, usually empirical, should be as effective as possible in order to assure rapid 
clinical resolution and reduce high rates of hospitalization and mortality especially affecting 
aged patients. New ﬂ  uoroquinolones with potent activity against the most important respiratory 
pathogens including Streptococcus pneumoniae, a key pathogen mainly in old patients with 
CAP, have been recently suggested by several international guidelines as monotherapy for the 
treatment of most CAP patient categories. Among newer derivatives, moxiﬂ  oxacin, an advanced 
generation 8-methoxy quinolone, has demonstrated good clinical and bacteriological efﬁ  cacy 
in large, well designed clinical trials both in adults and old patients with CAP, achieving also 
in aged people efﬁ  cacy comparable with that of standard treatments. Good pharmacokinetic 
characteristics such as excellent penetration into respiratory tract tissues and ﬂ  uids, optimal 
bioavailability, simplicity of once-daily dosing, and good tolerability, represent potential ad-
vantages of moxiﬂ  oxacin over other therapies. In addition, primarily due to a shorter length of 
hospital stay, moxiﬂ  oxacin has been shown to save costs compared with standard therapy. 
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Introduction
Pneumonia more frequently afﬂ  icts patients aged ≥65 years, with an incidence that 
increases proportionally with increasing age. It was estimated that ∼ 1 in 20 persons 
aged 85 years experiences a new community-acquired pneumonia (CAP) episode each 
year. Several factors such as comorbidities, nutritional status, cognitive impairment may 
contribute to the frailty and the increased susceptibility of these patients to pneumonia. 
Additionally, hospitalization, required in approximately 40% of episodes among elderly 
persons, is associated with a high risk of readmission within the following year and with 
high mortality rates (40%) (Janssens 2005; Schmidt-Ioanas and Lode 2006). 
Appropriate and timely antibiotic treatment is required for elderly patients in order 
to enhance the likelihood of a good clinical outcome. Patients requiring hospital ad-
mission for treatment of CAP should be promptly treated with potent broad spectrum 
intravenous antimicrobials in order to cover the major respiratory pathogens involved. 
Beta-lactam antibiotics have been commonly prescribed over the past decades for the 
treatment of outpatients and patients hospitalized with CAP; however, the emergence 
in recent years in several countries in the world of penicillin-resistant Streptococcus 
pneumoniae isolates (resistance rates ranging from less than 5% to over 50%) has 
forced a reassessment of the approach to treating CAP (Heffelﬁ  nger et al 2000).
In this context, recent ﬂ  uoroquinolones with antipneumococcal activity have been 
suggested as monotherapy in several international guidelines for the management of Clinical Interventions in Aging 2007:2(2) 180
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both outpatients and inpatients on a general medical ward 
and as a part of combination therapy for intensive care 
patients (BTS 2001; Niederman et al 2001; Mandell et al 
2003). Among the newest generation of ﬂ  uoroquinolones, 
moxiﬂ  oxacin has been shown to display excellent activity 
against the most important respiratory pathogens including 
multi-drug resistant pneumococcal strains, and to possess 
satisfactory pharmacokinetic and pharmacodynamic charac-
teristics at respiratory level (Balfour et al 2000; Zhanel et al 
2002). This review will focus on the efﬁ  cacy of moxiﬂ  oxacin 
in the treatment of elderly patients with CAP and on the safety 
and tolerability aspects of the drug in this population. 
CAP in the elderly
Pneumonia represents the leading infection-related cause of 
death and the ﬁ  fth cause of overall mortality in the geriatric 
population (Schmidt-Ioanas and Lode 2006). Several fac-
tors such as alcoholism, asthma, immunosuppression, lung 
and heart diseases, institutionalization, and increasing age 
have been found to be associated with an increased risk of 
pneumonia in the elderly. The clinical presentation of CAP 
in elderly patients is frequently characterized by a reduced 
prevalence of nonrespiratory symptoms and by the absence 
of the typical acute symptoms observed in young adults 
(Torres et al 1999; Loeb 2003; Niederman and Ahmed 2003; 
Schmidt-Ioanas and Lode 2006). Elderly people sometimes 
show only atypical clinical manifestations (eg, weakness, 
urinary incontinence, and changes in mental status). These 
atypical ﬁ  ndings could be responsible for a delay in diag-
nosis and treatment contributing to increased morbidity and 
mortality.
The term CAP should be reserved, in the elderly popu-
lation, for pneumonia acquired outside the nursing home 
setting, since nursing home-acquired pneumonia (NHAP) 
differs from CAP in terms of its etiology and clinical mani-
festations (Lieberman and Lieberman 2000). 
Although in most of the elderly the etiological agent 
of CAP remains undetermined because of the difﬁ  culty 
in attaining adequate bronchial specimens and/or con-
tamination of sputum by oral colonizing Gram-negative 
bacilli, S. pneumoniae represents the most frequently isolated 
pathogen in this population, accounting for up to 50% of 
the causative agents (Marrie 2000; Niederman et al 2001). 
Moreover, increasing age, per se, represents a risk factor 
for drug-resistant S. pneumoniae. Relatively high frequency 
is also reported in the elderly population for Haemophilus 
inﬂ  uenzae and Moraxella catarrhalis, while Staphylococcus 
aureus and Gram-negative bacteria occur less frequently in 
post-viral inﬂ  uenza and in high-risk patient groups, respec-
tively (Cunha 2001). Atypical pathogens, mainly Chlamydia 
pneumoniae, have been emphasized recently in old people as 
the cause of CAP and NHAP outbreaks with a high mortal-
ity rate in nursing homes. Outbreaks of pneumonia owing 
to respiratory viruses (inﬂ  uenza and respiratory syncytial 
viruses) may also occur in this population. Etiology of as-
piration pneumonia, which represents 5%–15% of CAP in 
elderly patients, in outpatients is associated with S. aureus, 
S. pneumoniae, and H. inﬂ  uenzae, while in hospitalized or 
nursing home residents more likely results in infection by 
Gram-negative rods. In addition, anerobes may also contrib-
ute to the pathogenesis of aspiration pneumonia, although 
evidence for their major role has not been conﬁ  rmed in recent 
studies (Schmidt-Ioanas and Lode 2006).
Despite advances in diagnosis and therapy, the manage-
ment of pneumonia still represents a challenge to the physi-
cians mainly in old patients. When respiratory infections 
occur, rapid diagnosis and prompt administration of appropri-
ate antibacterial therapy that ensures adequate coverage of 
the major pathogens causing CAP in old people is likely to 
increase the probability of a successful outcome, reducing the 
risk of hospitalization and death and preventing the spread of 
antimicrobial resistance (Rajagopalan and Yoshikawa 2001; 
Neralla and Meyer 2004).
The initial antibiotic therapy for elderly patients with 
CAP should be empirical and the selection of antibacterials 
should be based upon local resistance patterns of chosen 
drugs. The algorithm for therapy suggested by international 
guidelines recommends the use of either a selected beta-
lactam combined with a macrolide or monotherapy with a 
new antipneumococcal quinolone for both adult outpatients 
and inpatients (not in an intensive care unit) (Niederman 
et al 2001; BTS guidelines 2001; Mandell et al 2003). No 
difference in antimicrobial selection for elderly with CAP 
has been suggested by the recent Infectious Diseases Society 
of America update containing a new chapter on pneumonia 
in the elderly (Mandell et al 2003).
Moxiﬂ  oxacin: a “respiratory 
quinolone”
Moxiﬂ  oxacin, like other recent ﬂ  uoroquinolones, has a broad 
antibacterial spectrum that provides excellent coverage of 
the major respiratory tract pathogens. It displays excellent 
activity against Gram-negative bacilli (Enterobacteriaceae, 
H. inﬂ  uenzae, M. catarrhalis) and improved Gram-positive 
activity against S. pneumoniae (both penicillin-susceptible 
and penicillin-resistant strains), and S. aureus compared Clinical Interventions in Aging 2007:2(2) 181
Moxiﬂ  oxacin in elderly with community-acquired pneumonia 
with ciprofloxacin. Moreover, it retains good activity 
against atypical pathogens with a signiﬁ  cantly better anti-
bacterial effect against Legionella pneumophila compared 
with erythromycin, and displays improved activity against 
anerobes compared with ciproﬂ  oxacin (Zhanel et al 2002; 
Tano et al 2005).
Moxiﬂ  oxacin may inhibit both DNA gyrase and Topoi-
someras IV, but its mechanism of action is slightly different 
from that of other ﬂ  uoroquinolones. For S. pneumoniae the 
preferential target of ﬂ  uoroquinolone action appears to vary 
depending on the chosen antibacterial agent. Moxiﬂ  oxacin 
primarily targets the gyrA subunit of DNA gyrase, whereas 
levoﬂ  oxacin and other less recent derivatives such as oﬂ  oxacin 
and ciproﬂ  oxacin preferentially target the subunits parC or 
parE of the topoisomerase IV. Owing to this difference, moxi-
ﬂ  oxacin may retain high activity against increasingly common 
pneumococcal strains bearing substitutions in topoisomerase 
IV due to the wide use of old derivatives. In addition, due 
to modiﬁ  cation of the substituent at the C-7 position of the 
ﬂ  uoroquinolone structure, moxiﬂ  oxacin is a poor substrate for 
active efﬂ  ux in S. pneumoniae (Pestova et al 2000). 
Moxiﬂ  oxacin may be administered as oral and/or in-
travenous formulations with excellent bioavailability; the 
drug is well absorbed after oral administration and achieves 
good tissue penetration at respiratory level, reaching higher 
concentrations in alveolar macrophages (56.7 μg/mL) and 
epithelial lining ﬂ  uid (20.7 μg/mL) than in serum (3.2 μg/mL) 
after a single 400 mg oral dose (Soman et al 1999). Recently, 
high intrapulmonary concentrations have also been conﬁ  rmed 
in older adults (Capitano et al 2004). Moreover, moxiﬂ  oxacin 
both intravenously and orally exhibts high penetration in 
lung tissue with maximal lung concentrations of 12.37 μg/g 
and 16.21 μg/g for iv and oral administration respectively 
(Breilh et al 2003).
The pharmacokinetic behaviour of moxiﬂ  oxacin is not 
signiﬁ  cantly altered by the aging processes. This is consistent 
with moxiﬂ  oxacin being metabolized mainly by means of 
phase II hepatic reactions, the activity of which was shown 
not to decline with age (Pea et al 2006). Dose adjustment 
does not appear to be necessary in patients of advanced age 
or those with mild to moderate renal or hepatic impairment 
(Balfour and Lamb 2000; Ball et al 2004). The safety proﬁ  le 
of moxiﬂ  oxacin is in line with established ﬂ  uoroquinolones. 
Reactions of the gastrointestinal tract are the most often 
observed adverse effects during therapy. Like other ﬂ  uoro-
quinolones, moxiﬂ  oxacin can cause QT interval prolonga-
tion; therefore it should be avoided in patients with known 
prolongation of the QT interval, patients with uncorrected hy-
pokalemia or hypomagnesemia, and patients receiving class 
IA (eg, quinidine, procainamide) or class III (eg, amiodarone, 
sotalol) antiarrhytmic agents or other drugs such as certain 
antimicrobials (eg, erythromycin, halofantrine, pentami-
dine), certain antihistaminics (eg, astemizole, mizolastine, 
terfenadine), neuroleptics, and tricyclic antidepressive agents 
(Stahlmann and Lode 2003; Miravitlles 2005). Moxiﬂ  oxacin 
has a low propensity for causing phototoxic reactions and a 
low potential for causing excitatory effects and, like other 
agents of the group, can potentially cause tendon disorders 
mainly in aged patients in presence of concomitant use 
of corticosteroids and chronic renal diseases (Balfour and 
Lamb 2000; Zhanel et al 2002; Stahlmann and Lode 2003). 
Moxiﬂ  oxacin lacks other signiﬁ  cant drug interactions with a 
number of commonly prescribed drugs, although its absorp-
tion is decreased by concomitant administration of iron and 
cationic antacids (Ball et al 2004). 
Clinical efﬁ  cacy of moxiﬂ  oxacin 
in CAP
Clinical efﬁ  cacy of moxiﬂ  oxacin in CAP has been compared 
in some trials with different comparator agents both in adult 
and old patients (Table 1). All studies excluding those of 
Patel et al (2000), and Fogarty et al (2005) are comparative 
trials of moxiﬂ  oxacin versus standard therapies including 
beta-lactams (amoxicillin, amoxicillin-clavulanate, ceftri-
axone) alone or in combination with a macrolide (erythro-
mycin, roxithromycin, clarithromycin), a macrolide alone 
(clarithromycin), or another ﬂ  uoroquinolone, levoﬂ  oxacin 
(Fogarty et al 1999; Hoeffken et al 2001; Petitpretz 2001; 
Finch et al 2002; Torres et al 2003; Jardim et al 2003; Katz 
et al 2004; Portier et al 2005; Welte et al 2006; Anzueto et al 
2006). All these trials have conﬁ  rmed that moxiﬂ  oxacin is at 
least as effective as comparator regimens, since the overall 
clinical and bacteriological success rates for moxiﬂ  oxacin 
(range, 83%–97% and 77%–97%, respectively) are compa-
rable to those obtained for comparators (range, 80%–95% 
and 62%–93%, respectively). Aged subjects as a proportion 
of total number of patients included in these studies are not 
always available; clinical trials providing such demographic 
data (Petitpretz et al 2001; Torres et al 2003; Jardim et al 
2003; Portier et al 2005; Welte et al 2005), and the only 
study entirely carried out on a population of elderly patients 
(Anzueto et al 2006) will be brieﬂ  y summarized. 
Welte et al (2005) compared the efﬁ  cacy, safety, and 
speed and quality of defervescence of sequential intravenous 
or oral moxiﬂ  oxacin (400 mg od) and high dose ceftriaxone 
(2 g intravenously od) with or without erythromycin (1 g Clinical Interventions in Aging 2007:2(2) 182
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intravenously every 6–8 hours) for 7–14 days in patient 
with CAP requiring parenteral therapy. In both arms of the 
study the validated per-protocol (PP) population aged ≥65 
years achieved rates of 43.5% for moxiﬂ  oxacin and 41.0% 
for comparators respectively. Clinical response rates at the 
test of cure (TOC) visit in the validated PP population (317 
patients) were 85.7% in the moxiﬂ  oxacin group (138 of 161 
patients) and 86.5% in the ceftriaxone ± erythromycin group 
(135 of 156 patients); at the end of treatment, resolution was 
reported for 87.6% and 88.5% of patients for moxiﬂ  oxacin 
and for the other group respectively. In subgroups of patients 
matched for age, sex, and pneumonia severity index score, 
no signiﬁ  cant differences were observed at the TOC visit 
in both treatment groups. Compared with the ceftriaxone ± 
erythromycin, the moxiﬂ  oxacin regimen was observed to 
shorten the duration of hospitalization by a mean of 1.3 days 
in the validated PP population. In addition, defervescence 
and relief of signs and symptoms associated with CAP such 
as chest pain and weakness, occurred signiﬁ  cantly earlier in 
the moxiﬂ  oxacin-treated group than in the comparator-treated 
group. No relevant differences between treatment groups in 
the incidence for drug-related adverse events were observed 
and the vast majority of them were mild to moderate.
In a recent multicenter randomized open-label study, 
Portier et al (2005) compared 10 days oral treatment with 
moxiﬂ  oxacin (400 mg od) with amoxicillin–clavulanate 
(1000/125 mg tid) plus roxithromycin (150 mg bid) for non-
severe CAP in adults with risk factors. Patients aged >65 
years included in the intention-to-treat (ITT) analysis were 
46.8% (80/171) and 53.1% (93/175), respectively, and half 
of the entire population had at least one comorbid condition. 
Respective per-protocol clinical success rates at the TOC visit 
for moxiﬂ  oxacin and comparator were 131 of 151 (86.8%) 
and 120 of 138 (87.0%), with a 95% conﬁ  dence interval (CI) 
of –8.0 to 7.6 for the difference. Similar success rates were 
reached and maintained for patients with bacteriologically 
proven CAP and for those in whom the causative pathogen 
was S. pneumoniae. The bacteriological success rates at 
the TOC visit were also comparable for moxiﬂ  oxacin- and 
comparator-treated patients with respective success rates of 
23 of 30 (76.7%) and 23 of 31 (74.2%). Persistent clinical 
success rates at follow-up were 118 of 120 (98.3%) and 102 
of 106 (96.2%) with a 95% CI of –2.2 to 6.4 for the differ-
ence. The clinical success rates were also maintained when 
subgroups were analyzed according to risk factors such as 
age (>65 years), comorbidities, prior hospitalization, and 
alcohol consumption. The numbers of drug-related adverse 
events (predominantly digestive disorders) in the ITT 
population were comparable for both treatment arms: 24.6% 
(42 patients) for moxiﬂ  oxacin and 28.6% (50 patients) for 
comparator group.
Age 70 years was reported for 22% of moxiﬂ  oxacin-
treated patients (52/233) and for 18% of comparator-treated 
patients (44/244) of the ITT population, in the study of Tor-
res et al (2003). In this study, 564 patients were randomized 
to either oral moxiﬂ  oxacin (400 mg od) or to standard oral 
therapy (amoxicillin 1 g tid or clarithromycin 500 mg bid 
alone or in combination) for up to 14 days using a double-
blind procedure. In the PP population (446 patients), clini-
cal success was reported for 201 of 215 (93.5%) and 217 
of 231 (93.9%) in the moxiﬂ  oxacin and standard groups, 
respectively, at 7–10 days post-therapy. At 28–35 days 
follow-up, continued clinical cure was observed in 183 of 
192 (95.3%) moxiﬂ  oxacin and 207 of 221 (93.7%) standard 
groups. Moxiﬂ  oxacin treatment was signiﬁ  cantly better 
tolerated than standard regimens with fewer adverse events 
and premature discontinuation. Drug-related adverse events 
were reported in 55 of 274 (20%) moxiﬂ  oxacin and 86 of 
279 (31%) standard patients with a predominance of mild 
gastrointestinal upsets. 
The study of Jardim et al (2003) evaluated the efﬁ  cacy 
and safety of treatment with either moxiﬂ  oxacin or amoxicil-
lin administered for 10 days to patients suspected of having 
CAP caused by a pneumococcal infection. Over a total of 84 
patients (ITT population) included in the study and enrolled 
from 5 Latin American countries, 70 patients (PP population, 
34 patients for moxiﬂ  oxacin and 36 for amoxicillin) were 
evaluated at the end of the trial. In the ITT population patients 
aged >65 years comprised 28.2% (11/39) and 31.1% (14/45) 
of the moxiﬂ  oxacin and amoxicillin arm, respectively. The 
clinical success rate in the PP population at the ﬁ  nal visit after 
treatment was 94.1% (32/34) for moxiﬂ  oxacin and 91.7% 
(33/36) for amoxicillin, while the bacteriological success 
rate in microbiologically valid patients was 88.2% (15/17) 
and 87.5% (14/16), respectively. In terms of pneumococcal 
etiology 15 of 34 and 13 of 36 patients evaluated and treated 
with moxiﬂ  oxacin and amoxicillin, respectively, had proven 
pneumococcal pneumonia with prevalence of isolates with 
reduced susceptibility to penicillin. Drug-related adverse 
events in both treatment groups were mainly mild to moderate 
in intensity and were subsequently resolved. 
Petitpretz et al (2001) compared the efﬁ  cacy and safety 
of moxiﬂ  oxacin with amoxicillin for the treatment of mild-
to-moderate, suspected pneumococcal CAP in adult patients; 
25% and 22% respectively of the PP population (362 patients) 
were aged 70 years. Clinical success rate at the TOC visit Clinical Interventions in Aging 2007:2(2) 185
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in the PP population was 91.5% for moxiﬂ  oxacin and 89.7% 
for amoxicillin, while the clinical cure rate in patients with 
proven pneumococcal pneumonia was similar in both treat-
ment groups (87.8%). The bacteriological success rate in 
136 bacteriologically evaluable patients at the TOC visit 
was 89.7% for moxiﬂ  oxacin and 82.4% for amoxicillin. The 
bacteriological success rate against S. pneumoniae was 89.6% 
for moxiﬂ  oxacin and 84.8% for amoxicillin. The frequency of 
adverse events was comparable in both treatment groups.
Finally, the study of Anzueto et al (2006) was the ﬁ  rst com-
parative trial entirely carried out in hospitalized elderly patients 
(mean age 77.4 ± 7.7 years). In this double-blind, randomized 
trial, eligible patients for clinical efﬁ  cacy were stratiﬁ  ed by 
CAP severity to receive treatment with either intravenous/oral 
moxiﬂ  oxacin (400 mg od) or intravenous/oral levoﬂ  oxacin 
(500 mg od) for 7–14 days. Cure rates at the TOC visit for the 
clinically valid (PP) population (141 and 140 patients in the 
moxiﬂ  oxacin and levoﬂ  oxacin group, respectively) were 92.9% 
in the moxiﬂ  oxacin arm and 87.9% in the levoﬂ  oxacin arm 
(95% CI, –1.9 to 11.9; p = 0.2). Moreover, in subgroup analyses 
based on CAP severity and patient age, clinical cure rates in the 
moxiﬂ  oxacin arm were consistently higher than, although not 
statistically signiﬁ  cantly different from, those for levoﬂ  oxacin. In 
the moxiﬂ  oxacin group, cure rates were 92.6% for patients with 
mild or moderate CAP and 94.7% for patients with severe CAP, 
compared with cure rates of 88.6% and 84.6%, respectively, in 
the levoﬂ  oxacin group. Cure rates in the moxiﬂ  oxacin arm were 
90% for patients aged 65–74 years and 94.5% for patients aged 
75 years, compared with 85.0% and 90.0%, respectively, in 
the levoﬂ  oxacin arm. Bacteriological success at the TOC visit in 
the microbiologically valid population was 81.0% in the moxi-
ﬂ  oxacin arm (17 of 21 patients) and 75.0% in the levoﬂ  oxacin 
arm (21 of 28 patients) (p = 0.9). The bacteriological response 
was in agreement with the clinical response: clinical cure rates 
for the microbiologically valid population were 81.0% in the 
moxiﬂ  oxacin arm (17 of 21 patients) vs 76.7% in the levoﬂ  oxacin 
arm (23 of 30 patients) (95% CI, –0.22 to 0.31; p = 0.98). 
Although no differences emerged in duration of stay or 
duration of intravenous therapy between the two regimens, 
sequential intravenous/oral moxiﬂ  oxacin therapy provided 
signiﬁ  cantly higher clinical recovery rates by day 3–5 after 
initiation of treatment. No statistically signiﬁ  cant differences 
were observed between the treatment groups in drug-related 
adverse events. 
Safety considerations
Aging is well known to be associated with physiological 
changes and a higher risk of drug interactions; for these rea-
sons special attention needs to be directed towards the safety 
of medications in elderly people. Cumulative safety data from 
the most recent clinical trials and post-marketing surveillance 
studies including a large number of patients have shown that 
gastrointestinal complaints such as nausea, diarrhea, and 
dizziness were the most commonly reported drug-related 
adverse events (7.1, 5.2, and 2.6%, respectively) following 
administration of an oral dosage of 400 mg od (Ball et al 
2004). Gastrointestinal and central nervous system (CNS) 
disturbances are in line with those of other ﬂ  uoroquinolones; 
however, as adverse CNS reactions are of particular concern 
for the elderly, old patients with impairments of the CNS 
(eg, epilepsy, pronounced arteriosclerosis) should be treated 
with a quinolone only under close supervision (Stahlmann 
and Lode 2003). 
The safety of oral moxiﬂ  oxacin in adult and elderly pa-
tients pooled by age group (4939 patients aged <65 years, 842 
patients aged 65–74 years, 489 patients aged ≥75 years) has 
been evaluated in a retrospective analysis versus comparator 
(cefuroxime and clarithromycin, the most frequently used 
comparators) (Andriole et al 2005). Drug-related adverse 
event rates associated with oral moxiﬂ  oxacin or the com-
parator therapy used in these studies showed no signiﬁ  cant 
increase with advancing age. No arrhythmias related to cor-
rected QT interval prolongation were reported in this large 
group of young and elderly patients and a similar number 
of deaths was observed between the treatment groups (17 
moxiﬂ  oxacin, 19 comparator). The cardiac rhythm safety of 
moxiﬂ  oxacin versus levoﬂ  oxacin in high-risk elderly patients 
with CAP (eg, comorbid conditions and multiple medica-
tions) was recently evaluated in a randomized, double-blind 
trial (Morganroth et al 2005). In the studied population (394 
patients; two-third of the patients were >75 years old, and 
74.1% had a history of cardiac disease), iv/oral moxiﬂ  oxacin 
demonstrated a comparable cardiac rhythm safety proﬁ  le to 
iv/oral levoﬂ  oxacin; moreover, no deaths clearly related to 
study drugs were reported to occur during the observation 
period.
To date, sporadic moxiﬂ  oxacin-related adverse events 
observed in the elderly population may be limited to very 
few cases: these include tendinitis, in a 65-year-old female 
(Burkhardt et al 2004), nephrotoxicity in a 68-year-old 
woman who experienced acute tubulointerstitial nephritis 
developed approximately 10 days after the end of moxiﬂ  oxa-
cin therapy for a non-speciﬁ  c bronchial infection (Argirov 
et al 2005), and cholestasis in a 69-year-old man treated with 
moxiﬂ  oxacin because of a respiratory infection (Soto et al 
2002). Of major concern, several case reports have recently Clinical Interventions in Aging 2007:2(2) 186
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documented, mainly in old patients, a clinically relevant inter-
action between moxiﬂ  oxacin and warfarin with signiﬁ  cantly 
elevated international normalized ratio (INR) in patients 
receiving concomitant therapy (Arnold et al 2005; Elbe and 
Chang 2005). Routine, frequent INR monitoring and a suit-
able warfarin dosage adjustment should be recommended 
mainly in old patients receiving this combination of drugs. 
Conclusion
Pneumonia in the elderly is a serious illness that requires 
rapid management. The treatment of CAP is often based 
on an empirical approach; therefore, antibiotic choice must 
cover key pathogens and take into account, at the same time, 
the steady increase in resistance observed worldwide during 
recent years in important respiratory pathogens. Basically, 
the antibiotic therapy of CAP in the elderly should mainly 
cover S. pneumoniae, including the penicillin-resistant 
strains in countries with a high prevalence; when previous 
antimicrobial treatment, prior hospitalization, or structural 
lung disease are present, Pseudomonas aeruginosa should be 
suspected and should guide the antibiotic choice; and enteric 
Gram-negative rods and anerobes should be considered in 
residents of nursing homes and in suspicion of aspiration 
pneumonia. Isolates of penicillin- or macrolide-resistant 
pneumococci are now a consideration in elderly patients, 
as an age of >65 years represents a recognized risk factor 
for infection with these organisms. Given the increasing re-
sistance of S. pneumoniae to the traditional ﬁ  rst-line agents 
employed in CAP treatment, recent ﬂ  uoroquinolones with 
improved antipneumococcal activity are emerging as impor-
tant therapeutic options. Moxiﬂ  oxacin, thanks to its excellent 
microbiological, pharmacokinetic, and pharmacodynamic 
proﬁ  le, fulﬁ  ls all the requirements of an optimal antimi-
crobial agent useful for lower respiratory tract infections. 
Results of clinical trials available so far have shown that 
generally moxiﬂ  oxacin may achieve more than 90% cure in 
all patients irrespective of severity of pneumonia, patient’s 
age, and underlying comorbidities, and may retain bacterio-
logical and clinical efﬁ  cacy also in presence of penicillin-, 
macrolide- and multidrug-resistant pneumococcal isolates 
(Petitpretz et al 2001; Finch et al 2002; Jardim et al 2003; 
Fogarty et al 2005). In addition, moxiﬂ  oxacin therapy has 
been observed to be often associated with faster clinical 
recovery than comparator therapies. 
Finally, based on pharmacoeconomic considerations, the 
option of moxiﬂ  oxacin sequential therapy, leading to early 
discharge from the hospital, may save costs compared with 
standard therapy (Drummond et al 2003). 
Proven clinical and bacteriological efﬁ  cacy and safety 
proﬁ  le in line with established ﬂ  uoroquinolones and com-
parator agents suggest that moxiﬂ  oxacin should prove a suc-
cessful agent for the treatment of elderly patients with CAP. 
The growing use of the new-generation ﬂ  uoroquinolones 
could, however, lead to emergence of resistant pneumococcal 
isolates; although resistance is currently low, levoﬂ  oxacin 
clinical failures in the management of pneumococcal pneu-
monia have been reported recently, requiring a re-evaluation 
of the newer agents (Ferrara 2005). No reports have shown 
the same phenomenon in patients treated with the more active 
moxiﬂ  oxacin, suggesting that the selection of the most potent 
ﬂ  uoroquinolone, which may assure the best coverage against 
S. pneumoniae, will reduce the opportunity for resistance to 
develop. However, to preserve the activity of moxiﬂ  oxacin 
for the future, it seems prudent to avoid the massive use of 
this new agent as long as effective standard antibiotics for 
the treatment of CAP are still available.
Targeted and judicious use of newer ﬂ  uoroquinolones in 
selected CAP patients, including those with infection owing 
to highly-resistant pneumococci, or following treatment 
failure with ﬁ  rst-line regimen, will minimize the emergence 
of bacterial resistance to the entire class and maintain class 
efﬁ  cacy (Heffelfnger et al 2000).
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